The archive
391 stories, newest first — page 1 of 17.
Innovation & Devices
An FDA Class I recall covers Luna G3 APAP model LG3600 with specified firmware. Clinicians and suppliers need to identify exposed patients and protect continuity of positive airway pressure therapy.
Rayan Salih · 6 min read
Innovation & Devices
Certain ResMed Astral 100 and 150 ventilators require correction because supercapacitor leakage may contribute to failure. Ventilator-dependent patients need prompt device checks and reliable backup plans.
Rayan Salih · 6 min read
Endocrinology & Metabolism
The Endocrine Society advises against routine brain MRI for girls ages 6–8 and boys ages 8–9 with central precocious puberty and no neurologic signs.
Rayan Salih · 6 min read
Oncology
The FDA approved imlunestrant plus abemaciclib for adults with ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy progression.
Rayan Salih · 6 min read
Cardiology
ITACS addresses IV iron before cardiac surgery, but the supplied citation lacks the numerical results needed to determine whether it reduces transfusion or improves recovery.
Rayan Salih · 6 min read
Oncology
FDA accelerated approval makes tumor HER2 kinase-domain mutation status treatment-defining for eligible adults with previously treated, advanced nonsquamous NSCLC.
Rayan Salih · 7 min read
Innovation & Devices
A Class I recall of certain Impella CP SmartAssist sets follows persistent low-purge-pressure alarms that may interrupt support. Hospitals should identify affected inventory and plan for monitored pump exchange.
Rayan Salih · 6 min read
Neurology
The FDA approved apitegromab for patients aged 2 years or older with spinal muscular atrophy who are already receiving an SMN2-targeted treatment.
Rayan Salih · 7 min read
Women's Health
The FDA approved first-line sacituzumab govitecan alone for patients unable to receive checkpoint inhibition and with pembrolizumab for PD-L1–positive advanced triple-negative breast cancer.
Rayan Salih · 7 min read
Cardiology
Across 35 randomized trials, high-dose omega-3 treatment was associated with higher atrial fibrillation risk. The absolute increase was modest but relevant for cardiovascular patients.
Rayan Salih · 6 min read
Cardiology
Across randomized heart-failure trials, SGLT2 inhibitors most reliably reduce worsening heart failure and cardiovascular death. Evidence for lower all-cause mortality is less secure.
Rayan Salih · 7 min read
Oncology
MATTERHORN found better event-free survival and pathologic response with perioperative durvalumab plus FLOT for resectable gastric or gastroesophageal junction adenocarcinoma.
Rayan Salih · 7 min read
Women's Health
The FDA approved imlunestrant plus abemaciclib for adults with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer that progressed after endocrine therapy.
Rayan Salih · 6 min read
Neurology
Pooled evidence found no significant difference in functional independence or symptomatic intracerebral hemorrhage when CT perfusion and noncontrast CT were used to select patients for acute ischemic stroke treatment.
Dr. Abu Bakar · 6 min read
Health Policy
FDA materials recommend keeping three unapproved peptides off the 503A Bulks List, a step that could sharply restrict traditional pharmacies’ ability to compound them from bulk ingredients.
Dr. Abu Bakar · 6 min read
Cardiology
A 2026 meta-analysis found that digitalis glycosides reduced worsening heart failure events, but not cardiovascular death, reinforcing a selective rather than routine role.
Dr. Abu Bakar · 7 min read
Endocrinology & Metabolism
WHO is calling for stronger safety monitoring as GLP-1 use for weight loss grows worldwide. Clinicians need reliable prescribing, follow-up and adverse-event reporting systems.
Dr. Abu Bakar · 7 min read
Clinical Briefs
The FDA reported 184 serious injuries and no deaths involving specified Medtronic and Given Imaging esophageal pH capsule delivery devices. Gastroenterology services should review inventory, workflows and follow-up.
Rayan Salih · 7 min read
Cardiology
FDA approval adds baxdrostat as an aldosterone-targeted option for adults whose hypertension remains uncontrolled on combination therapy.
Rayan Salih · 7 min read
Infectious Disease
WHO has issued a unified framework for clinicians and outbreak teams managing Ebola and Marburg disease, linking supportive care with infection prevention, workforce protection, and coordinated response.
Rayan Salih · 7 min read
Oncology
Interim phase 3 results favor adding sacituzumab tirumotecan to first-line pembrolizumab for PD-L1-positive advanced NSCLC, but survival, safety and generalizability remain unsettled.
Rayan Salih · 6 min read
Oncology
FDA accelerated approval applies to previously treated, advanced non-squamous NSCLC with qualifying activating mutations in the HER2 tyrosine kinase domain—not every ERBB2 alteration.
Rayan Salih · 6 min read
Infectious Disease
A CDC alert describes increased reports of human rabies exposures nationwide. Clinicians need a rapid workflow for exposure assessment, public health consultation and correctly delivered prophylaxis.
Rayan Salih · 7 min read
Oncology
The FDA approved an allogeneic regulatory T-cell therapy for adults with hematologic malignancies undergoing matched-donor stem cell transplantation. Programs must assess eligibility, logistics and safety readiness.
Rayan Salih · 6 min read